Rosuvastatin
HMG-CoA reductase inhibitor · “The hsCRP-driven prescription”
The Clinical Case
Female, 62 yo. No prior CVD. LDL 2.4 mmol/L (apparently normal), but hsCRP persistently 4.2 mg/L. Non-smoker, no diabetes. Cardiologist initiates lipid therapy despite "normal" LDL, citing a landmark primary prevention trial that specifically enrolled patients with this inflammatory profile. Patient is of East Asian origin — dose adjustment required.
The Answer
Played on: 2 Jan 2026 · 16 Jan 2026 · 30 Jan 2026 · 13 Feb 2026 · 27 Feb 2026 · 13 Mar 2026 · 27 Mar 2026 · 10 Apr 2026 · 24 Apr 2026 · 8 May 2026 · 22 May 2026 · 5 Jun 2026 · 19 Jun 2026 · 3 Jul 2026 · 17 Jul 2026 · 31 Jul 2026 · 14 Aug 2026 · 28 Aug 2026
Clinical Pearl
Evidence: JUPITER trial: 44% RRR in CV events in patients with normal LDL but elevated hsCRP — reshaped treatment thresholds
All Hints
Evidence: JUPITER trial: 44% RRR in CV events in patients with normal LDL but elevated hsCRP — reshaped treatment thresholds
Efficacy: Most potent statin: ~55% LDL reduction at 40 mg; at equal 10 mg doses reduces LDL by 46% vs 37% for atorvastatin; also raises HDL by ~10%
Pharmacokinetics: Half-life 19 h → any time of day dosing; minimal CYP2C9 metabolism (not CYP3A4) → fewer drug interactions than atorvastatin
Asian dosing: Halve starting dose in Asian patients — SLCO1B1 pharmacogenomics cause higher plasma exposure
Renal: Partial renal excretion — dose adjust at eGFR <30 mL/min
Think you can beat today's puzzle?
A new clinical case every day. 6 guesses to name the drug.
Play today's Med Wordle — #240 →